ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Two-Year Outcomes of Treatment-Experienced Adults After Programmatic Transitioning to Dolutegravir: Longitudinal Data From the VICONEL Human Immunodeficiency Virus Cohort in Lesotho.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy.The Journal of antimicrobial chemotherapy · 2026Article
- Longitudinal Outcomes of Dolutegravir-Based Antiretroviral Therapy in a Large Nigerian Programmatic HIV-1 Cohort, 2017-2019.Open forum infectious diseases · 2026Article
- Virological impact of the programmatic dolutegravir transition at Mildmay Hospital Uganda: a before-and-after cohort study with subgroup and trajectory analysis, 2016-2023.BMC infectious diseases · 2026Article
- One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials.Open forum infectious diseases · 2026Article
- Virologic outcomes among people living with HIV on dolutegravir-based antiretroviral therapy in Kenya, 2018-2024: a comparison retrospective longitudinal analysis.The Lancet regional health. Africa · 2026Article
- Estimates and predictors of HIV viral non-suppression in South African adults on antiretroviral treatment.Journal of the International AIDS Society · 2026Article
- Viral Suppression, Viral Failure, and Safety Outcomes in Children and Adolescents With HIV on Dolutegravir in Europe and Thailand.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- High rates of viral suppression in pregnancy drop postpartum in South African women on tenofovir-lamivudine-dolutegravir: a prospective cohort study.Journal of the International AIDS Society · 2025Article
- Three-Year Outcomes After Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti.Open forum infectious diseases · 2025Article
- Article
- Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Observational
- Viral suppression in adults on efavirenz- or dolutegravir-based antiretroviral therapy in Mopani District, South Africa.Southern African journal of HIV medicine · 2025Article
- Pharmacoeconomic perspectives on HIV: integrating data for long-term treatment and prevention.Frontiers in medicine · 2025Review
- Emergence of Acquired Dolutegravir Resistance in Treatment-experienced People With HIV in Lesotho.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- HIV viral suppression in the era of dolutegravir use: Findings from a national survey in Tanzania.PloS one · 2024Article
- Viral Load Monitoring Practices and Correlates of Viral Non-suppression Among Children and Young Adolescents Living With HIV in Kiambu County, Kenya.Sage open pediatricsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In the Viral Load Cohort North-East Lesotho (VICONEL) human immunodeficiency virus cohort, 14 242 adults had transitioned from efavirenz- or nevirapine-based antiretroviral therapy (ART) to dolutegravir-based ART by October 2021. Rates of viral suppression to <50 copies/mL were 84.8%, 93.9%, and 95.4% before, 12 months after, and 24 months after transition, respectively. Sex, age, pretransition viral load, and treatment backbone correlated with 24-month viremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.